Active, Not Recruiting
Study of Retinfanlimab in Combination With INCAGN02385 and INCAGN02390 as First-Line Treatment in Participants With PD-L1-Positive (CPS ≥ 1) Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck
NCT05287113
- Conditions
- Carcinoma, Carcinoma, Squamous Cell, Head and Neck Cancer, +6 more
- Locations
-
- Mayo Clinic Rochester Scottsdale, Arizona, United States
- City of Hope National Medical Center Duarte, California, United States
- City of Hope Orange County Irvine, California, United States
- University of California San Diego Medical Center, Moores Cancer Center La Jolla, California, United States